Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

近期，昆明市第一人民医院呼吸与危重症医学科的金志贤和陈敏团队在《Cancer Cell International》上发表了题为“SPP1 promotes cancer stemness and reduces osimertinib ...

《难治性肺癌中国专家共识》的发布，填补了我国该领域无统一诊疗规范的空白，通过 “定义 - 分类 - 分层治疗 - 新技术” ...

近年来，抗体偶联药物（ADC）凭借其「精准递送」与「强效杀伤」的双重优势，在肺癌治疗领域掀起了一场深刻的变革。它不仅在 HER2、MET 等罕见驱动基因突变非小细胞肺癌（NSCLC）中确立了精准治疗新路径，更在长期缺乏突破的小细胞肺癌（SCLC）后线治疗中展现出令人瞩目的潜力。其中，德曲妥珠单抗（T-DXd）在 HER2 突变 ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

Key opportunities in the Global Small Cell Lung Cancer Therapeutics Market include the growing demand for advanced ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune system better recognize and respond to small cell lung cancer. The study aims to ...

需要理解的是，不同患者的复发风险并不完全相同。分期越靠后、存在淋巴结受累、脉管侵犯等高危病理因素时，术后复发的可能性也会相应增加。例如，有回顾性研究显示在可手术的EGFR突变非小细胞肺癌患者中，IA期的2年无病生存（DFS）率为81%，而分期更晚的I ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...